BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31352238)

  • 1. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis.
    Guo Y; Yue P; Wang Y; Chen G; Li Y
    Biomed Pharmacother; 2019 Oct; 118():109255. PubMed ID: 31352238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.
    Mei J; Liu G; Li R; Xiao P; Yang D; Bai H; Hao Y
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34821362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
    Wang M; Zhang R; Zhang S; Xu R; Yang Q
    Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a.
    Li Y; Lv S; Ning H; Li K; Zhou X; Xv H; Wen H
    Biomed Pharmacother; 2018 Dec; 108():1775-1782. PubMed ID: 30372881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCP5 contributes to cisplatin resistance in gastric cancer through miR-128/HMGA2 axis.
    Liang L; Kang H; Jia J
    Cell Cycle; 2021 Jun; 20(11):1080-1090. PubMed ID: 33993846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer.
    Wu C; Hu Y; Ning Y; Zhao A; Zhang G; Yan L
    Cancer Biother Radiopharm; 2020 Dec; 35(10):741-752. PubMed ID: 32407172
    [No Abstract]   [Full Text] [Related]  

  • 8. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p.
    Liu YY; Zhang LY; Du WZ
    Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31793989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2.
    Li H; Ma X; Yang D; Suo Z; Dai R; Liu C
    J Cell Biochem; 2020 Feb; 121(2):1353-1361. PubMed ID: 31478258
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chi C; Mao M; Shen Z; Chen Y; Chen J; Hou W
    Hum Gene Ther; 2018 Dec; 29(12):1438-1448. PubMed ID: 29896986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
    Zhou X; Jin W; Jia H; Yan J; Zhang G
    J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
    Chen J; Li Y; Li Z; Cao L
    J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA PCAT-1 promotes the progression of osteosarcoma via miR-508-3p/ZEB1 axis.
    Chang L; Jia DL; Cao CS; Wei H; Li ZQ
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2517-2527. PubMed ID: 33829438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.
    Huang G; Cai G; Hu D; Li J; Xu Q; Chen Z; Xu B
    Cell Oncol (Dordr); 2022 Dec; 45(6):1329-1346. PubMed ID: 36214997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204.
    Zhou H; Ma Y; Zhong D; Yang L
    Biomed Pharmacother; 2019 Apr; 112():108633. PubMed ID: 30784927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of cir_RNA PVT1 Elevates Gastric Cancer Cisplatin Sensitivity via Sponging miR-152-3p.
    Wang X; Zhang Y; Li W; Liu X
    J Surg Res; 2021 May; 261():185-195. PubMed ID: 33444948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.
    Fang Q; Chen X; Zhi X
    Med Sci Monit; 2016 Oct; 22():3506-3513. PubMed ID: 27694794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.